AbbVie has announced the first patient dosing in a global Phase 3 trial of upadacitinib for the treatment of moderate to severe hidradenitis suppurativa (HS), a chronic, inflammatory disease with limited therapeutic options. The trial, named Step-Up HS, is the first registered, randomized Phase 3 trial in HS and aims to enroll approximately 1,300 participants across 275 sites worldwide. The primary endpoint will measure the percentage of participants achieving a 50% reduction in the total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count relative to baseline at week 16.